From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India

Indian J Ophthalmol. 2022 Aug;70(8):3073-3076. doi: 10.4103/ijo.IJO_3082_21.

Abstract

Purpose: To describe the increase in prevalence of ethambutol-induced optic neuropathy (EON) in patients presenting to a single tertiary referral eye care center in India after introduction of weight-based fixed dose combinations and an increase in duration of ethambutol use from 2016 in the Revised National Tuberculosis Control Program.

Methods: This was a retrospective, observational, referral hospital-based study of 156 patients with a diagnosis of EON presenting to a single tertiary referral eye care center between January 2016 and December 2019. The main outcome measure was to assess the increase in prevalence of EON cases presenting to our tertiary care institute.

Results: During the 4-year study period, 156 new patients were diagnosed with EON. A total of 101 patients (64.7%) were males and 55 (35.3%) were females. The most common age group affected was 41-60 years. The significant complaint at presentation was decreased vision in all the patients. A rising trend in the number of patients diagnosed as EON was seen, with the prevalence increasing from 16 cases in 2016, 13 cases in 2017, and 31 cases in 2018 to 96 cases in 2019.

Conclusion: The results of this study indicated an alarming increase in the trend of EON cases presenting to our tertiary care institute.

Keywords: Antitubercular Therapy; RNTCP; Revised National Tuberculosis Control Program; ethambutol toxicity; fixed dose combination.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Antitubercular Agents / adverse effects
  • Drug Combinations
  • Ethambutol / adverse effects
  • Female
  • Humans
  • India / epidemiology
  • Male
  • Middle Aged
  • Optic Nerve Diseases* / chemically induced
  • Optic Nerve Diseases* / diagnosis
  • Optic Nerve Diseases* / epidemiology
  • Tuberculosis*

Substances

  • Antitubercular Agents
  • Drug Combinations
  • Ethambutol